2. Search Result
Search Result
Results for "

apical

" in MedChemExpress (MCE) Product Catalog:

61

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Peptides

1

MCE Kits

3

Natural
Products

1

Recombinant Proteins

7

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109120
    Odevixibat
    4 Publications Verification

    A4250

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat
  • HY-107903
    Thyroglobulin

    Thyroglobulin from bovine

    		 Biochemical Assay Reagents Cancer
    Thyroglobulin is a 660 kDa, dimeric glycoprotein produced by the follicular cells of the thyroid and used entirely within the thyroid gland. Thyroglobulin acts as a substrate for the synthesis of the thyroid hormones thyroxine (T4) and triiodothyronine (T3), as well as the storage of the inactive forms of thyroid hormone and iodine within the follicular lumen of a thyroid follicle. Thyroglobulin activates Akt kinase activity in FRTL-5 thyroid cell .
    Thyroglobulin
  • HY-W014622
    CRT0044876
    2 Publications Verification

    		 DNA/RNA Synthesis Cancer
    CRT0044876 is a potent and selective apurinic/apyrimidinic endonuclease 1 (APE1) inhibitor (IC50=~3 μM). CRT0044876 inhibits the AP endonuclease, 3′-phosphodiesterase and 3′-phosphatase activities of APE1, and is a specific inhibitor of the exonuclease III family of enzymes to which APE1 belongs. CRT0044876 potentiates the cytotoxicity of several DNA base-targeting compounds .
    CRT0044876
  • HY-19357
    Erenapurstat
    4 Publications Verification

    E3330; APX-3330

    		 DNA/RNA Synthesis NF-κB AP-1 HIF/HIF Prolyl-Hydroxylase VEGFR Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Cancer
    Erenapursta (E3330) is a direct, orally active and selective inhibitor of Ape-1 (apurinic/apyrimidinic endonuclease 1)/Ref-1 (redox factor-1) redox. Erenapursta is able to impair tumor growth and blocks the activity of NF-κB, AP-1, and HIF-1α in pancreatic cancer. Erenapursta shows anticancer activities .
    Erenapurstat
  • HY-16643
    Linerixibat
    Maximum Cited Publications
    13 Publications Verification

    GSK2330672

    		 Apical Sodium-Dependent Bile Acid Transporter Infection Metabolic Disease Inflammation/Immunology
    Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .
    Linerixibat
  • HY-B1099
    Hycanthone
    2 Publications Verification

    		 DNA/RNA Synthesis Topoisomerase Parasite Infection
    Hycanthone is a thioxanthenone DNA intercalator and inhibits RNA synthesis as well as the DNA topoisomerases I and II. Hycanthone inhibits nucleic acid biosynthesis and inhibits apurinic endonuclease-1 (APE1) by direct protein binding with a KD of 10 nM. Hycanthone is a bioactive metabolite of Lucanthone (HY-B2098) and has anti-schistosomal agent .
    Hycanthone
  • HY-B2098
    Lucanthone

    		Autophagy Parasite Cancer
    Lucanthone is an endonuclease inhibitor of Apurinic endonuclease-1 (APE-1).
    Lucanthone
  • HY-136731
    APE1-IN-1

    		DNA/RNA Synthesis Cancer
    APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/apyrimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC50 value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate and Temozolomide (HY-17364) to cancer cells .
    APE1-IN-1
  • HY-101190
    Volixibat

    SHP626; LUM002

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH) .
    Volixibat
  • HY-B1363
    Bendroflumethiazide

    Bendrofluazide

    		 NKCC Cardiovascular Disease
    Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .
    Bendroflumethiazide
  • HY-18713
    CRT0066854

    		PKC ROCK Neurological Disease Inflammation/Immunology
    CRT0066854 is a potent and selective atypical PKC isoenzymes inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
    CRT0066854
  • HY-148447
    eIF4A-IN-3

    		Eukaryotic Initiation Factor (eIF) Cancer
    eIF4A-IN-3, Silvestrol (HY-13251) analogue, is an eIF4A inhibitor. eIF4A-IN-3 blocks protein translation initiation by interfering with eIF4F complex assembly, preferentially inhibiting translation of mRNAs with long, highly structured 5'-untranslated regions. eIF4A-IN-3 inhibits proliferation of human breast cancer cells. eIF4A-IN-3 has moderate apical to basolateral permeability in intestinal cell monolayers and a low efflux ratio .
    eIF4A-IN-3
  • HY-N7755
    Estradiol 3-glucuronide sodium

    		Endogenous Metabolite ATP-binding cassette (ABC) transporters OAT Others
    Estradiol 3-glucuronide sodium is an estrogen metabolite, which is a glucuronide conjugate formed by the catalysis of uridine diphosphate glucuronosyltransferase in tissues such as the liver from Estradiol (HY-B0141). Estradiol 3-glucuronide sodium is a potent substrate of Mrp2, with an S50 of 55.7 μM. Estradiol 3-glucuronide sodium achieves hepatobiliary transport in hepatocytes through basolateral uptake via OATP1B1, OATP1B3 and OATP2B1, as well as apical efflux via MRP2 and BCRP .
    Estradiol 3-glucuronide sodium
  • HY-126584
    H-Val-Val-OH

    Val-Val

    		 Drug Intermediate Oligopeptide Cotransporter Others
    H-Val-Val-OH (Val-Val) is a stereochemistry-dependent substrate and inhibitor of apical oligopeptide transporters. H-Val-Val-OH undergoes apical intracellular accumulation in human intestinal cells via carrier-mediated transport, and inhibits the uptake of Cephalexin (HY-B0200) through interaction with transporters. Substitution of L-valine with D-valine in H-Val-Val-OH abolishes its binding ability to apical oligopeptide transporters .
    H-Val-Val-OH
  • HY-18713A
    CRT0066854 hydrochloride

    		PKC ROCK Neurological Disease
    CRT0066854 hydrochloride is a potent and selective atypical PKCs inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
    CRT0066854 hydrochloride
  • HY-135259
    CAY10580

    		Prostaglandin Receptor Metabolic Disease
    CAY10580 is a potent and selective prostaglandin EP4 receptor agonist (Ki=35 nM) .
    CAY10580
  • HY-130487
    miR-21-IN-2

    		MicroRNA Cancer
    miR-21-IN-2 is a high-affinity miR-21 inhibitor. miR-21-IN-2 binds to the apical loop region of the pre-miR-21 hairpin, inhibits Dicer-mediated processing, and thereby blocks the biosynthesis of mature miR-21. miR-21-IN-2 can be used for the research of microRNA-related diseases .
    miR-21-IN-2
  • HY-W585842
    Estradiol 3-glucuronide

    		Endogenous Metabolite ATP-binding cassette (ABC) transporters OAT Others
    Estradiol 3-glucuronide is an estrogen metabolite, which is a glucuronide conjugate formed from Estradiol (HY-B0141) via catalysis by uridine diphosphate glucuronosyltransferases in tissues such as the liver. Estradiol 3-glucuronide is a potent substrate of Mrp2, with an S50 value of 55.7 μM. Estradiol 3-glucuronide achieves hepatobiliary transport in hepatocytes through basolateral uptake via OATP1B1, OATP1B3 and OATP2B1, as well as apical efflux via MRP2 and BCRP .
    Estradiol 3-glucuronide
  • HY-136450
    Triclabendazole sulfoxide

    TCBZ-SO

    		 Parasite BCRP Infection Cancer
    Triclabendazole sulfoxide (TCBZ-SO) is an orally active ABCG2 inhibitor with antiparasitic activity. Triclabendazole sulfoxide inhibits ABCG2-mediated active efflux and ATPase activity. Triclabendazole sulfoxide increases the intracellular accumulation of Mitoxantrone (HY-13502). Triclabendazole sulfoxide reduces the apical-directed transepithelial transport of Nitrofurantoin and Danofloxacin, while increasing their basolateral-directed transepithelial transport. Triclabendazole sulfoxide elevates the plasma levels of sulfasalazine in wild-type mice. Triclabendazole sulfoxide decreases ABCG2-mediated secretion of Nitrofurantoin into milk in wild-type lactating mice. Triclabendazole sulfoxide can be used in the research of insecticidal agents and cancers such as breast cancer .
    Triclabendazole sulfoxide
  • HY-148795
    Ritivixibat

    		Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Ritivixibat is an apical sodium-dependent bile acid transporter (ASBT/IBAT) inhibitor. Ritivixibat blocks ASBT/IBAT function, thereby reducing bile acid reabsorption, regulating bile acid homeostasis and alleviating liver injury. Ritivixibat protects cholangiocytes from damage caused by cytotoxic bile acids. Ritivixibat is applicable to research related to primary sclerosing cholangitis .
    Ritivixibat
  • HY-120069
    APX2009

    		Apoptosis Cancer
    APX2009 is a specific APE1/REF-1 redox inhibitor with anticancer activities which decreases the proliferative, migratory, and invasive properties of breast cancer cell and induces apoptosis in breast cancer cell .
    APX2009
  • HY-119993
    AR03

    BMH-23

    		 DNA/RNA Synthesis Cancer
    AR03 (BMH-23) is an apurinic/apyrimidinic endonuclease 1 (Ape1) inhibitor with an IC50 of 2.1 µM. AR03 has low affinity for double-stranded DNA. AR03 potentiates the cytotoxicity of methyl methanesulfonate and temozolomide in SF767 cells .
    AR03
  • HY-155774
    VU533
    1 Publications Verification

    		 Phospholipase Metabolic Disease
    APE-PLD (VU533) activator is a potent NAPE-PLD activator with an EC50 value of 0.30 µM. NAPE-PLD activator (VU533) can enhance NAPE-PLD activity and increase efferocytosis by macrophages. NAPE-PLD activator (VU533) can be used for cardiometabolic diseases research .
    VU533
  • HY-151883
    APE1-IN-2

    		Apoptosis MDM-2/p53 Cancer
    APE1-IN-2 (compound AP1) is a Pt(IV) proagent, targeting a critical BER protein, apurinic/apyrimidinic endonuclease 1 (APE1). APE1-IN-2 shows anticancer activity. APE1-IN-2 induces intracellular accumulation of platinum and activates DNA damage response and apoptosis signals .
    APE1-IN-2
  • HY-100210A
    FN-439 TFA

    		MMP Inflammation/Immunology Cancer
    FN-439 TFA is a selective collagenase-1 inhibitor. FN-439 TFA inhibits collagenase-1 with an IC50 value of 1 μM. FN-439 TFA can be used for the research of cancer and inflammation .
    FN-439 TFA
  • HY-B1363S
    Bendroflumethiazide-d5

    Bendrofluazide-d5

    		 Isotope-Labeled Compounds NKCC Cardiovascular Disease
    Bendroflumethiazide-d5 (Bendrofluazide-d5) is the deuterium labeled Bendroflumethiazide (HY-B1363).Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .
    Bendroflumethiazide-d5
  • HY-B1363R
    Bendroflumethiazide (Standard)

    Bendrofluazide (Standard)

    		 NKCC Reference Standards Cardiovascular Disease
    Bendroflumethiazide (Standard) (Bendrofluazide (Standard)) is the analytical standard of Bendroflumethiazide (HY-B1363). This product is intended for research and analytical applications. Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .
    Bendroflumethiazide (Standard)
  • HY-E70425
    Sucrose synthase

    		Glycosyltransferase Metabolic Disease
    Sucrose synthase belongs to glycosyltransferases and is a reversible catalyst present in plants, which catalyzes the conversion of sucrose into fructose and UDP-G or ADP-G. Sucrose synthase localizes to the cytoplasm, plasma membrane, cell wall, vacuole and mitochondria of plants. Sucrose synthase regulates sugar metabolism, supports the development of taproots, fruits, seeds and vascular tissues, drives the synthesis of starch, cellulose and callose, and enhances nitrogen fixation capacity. Sucrose synthase mediates signal transduction in plant meristems. Sucrose synthase is associated with plant growth, anaerobic stress tolerance, as well as shoot apical meristem and leaf morphology; overexpression of this enzyme promotes plant growth, increases xylem size, and elevates cellulose and starch contents .
    Sucrose synthase
  • HY-175595
    ADEP-14

    ADEP26

    		 ClpP Bacterial Infection
    ADEP-14 (ADEP26) is a ClpP activator. ADEP-14 exhibits antibacterial activity against Gram-negative and Gram-positive bacteria. ADEP-14 can be used in studies related to bacterial infections .
    ADEP-14
  • HY-126425
    NCGC00262650

    		Parasite Infection
    NCGC00262650 is a potent apical membrane antigen 1-rhoptry neck protein 2 (AMA1-RON2) interaction inhibitor. NCGC00262650 can block entry of merozoites into red blood cells with an IC50 of 9.8 μM .
    NCGC00262650
  • HY-NP014
    Protein A-PE

    		Biochemical Assay Reagents Others
    Protein A-PE is a biochemical reagent that can be used as a biological material or organic compound for life science related research .
    Protein A-PE
  • HY-129982
    SC-435

    		Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
    SC-435
  • HY-149442
    APE1-IN-3

    		DNA/RNA Synthesis Cancer
    APE1-IN-3 (Compound 1) is a APE1 inhibitor. APE1-IN-3 can be used for the research of cancer .
    APE1-IN-3
  • HY-15131
    PNRI-299

    		Interleukin Related Inflammation/Immunology
    PNRI-299 is a selective AP-1 transcription inhibitor with an IC50 of 20 uM. PNRI-299 is a selective APE/Ref-1 inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM). PNRI-299 significantly reduces airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model .
    PNRI-299
  • HY-15790H
    (S)-Elobixibat

    (S)-A 3309; (S)-AZD 7806

    		 Apical Sodium-Dependent Bile Acid Transporter TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology
    (S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to study metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .
    (S)-Elobixibat
  • HY-19133
    ME 3407

    EF-4040

    		 Na+/K+ ATPase Myosin PKA Metabolic Disease
    ME-3407 (EF-4040) is a H +-K +-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H +-K +-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer .
    ME 3407
  • HY-P3347
    NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal)

    		Apelin Receptor (APJ) Cardiovascular Disease
    NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) (compound 40), a macrocyclic analogue of Ape13, is a potent APJ agonist (Ki=5.7 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) exhibits a favorable Gα12-biased signaling and an increased in vivo half-life .
    NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal)
  • HY-179014
    OGG1 activator-1

    		DNA Glycosylase Neurological Disease Inflammation/Immunology Cancer
    OGG1 activator-1 (Compound 30) is a selective 8-oxoguanine DNA glycosylase-1 (OGG1) activator with an AC50 value of 0.58 μM. OGG1 activator-1 does not activate nor inhibit the key downstream repair enzyme APE1, and shows > 150-fold selectivity for the activation effect on OGG1. OGG1 activator-1 exhibits extremely high metabolic stability and almost no cytotoxicity. OGG1 activator-1 can be used for the study of oxidative stress-related diseases (such as neurodegenerative diseases, fibrotic diseases, cancer, inflammation, etc.) .
    OGG1 activator-1
  • HY-N3625
    Coronalolic acid

    Coronalonic acid

    		 NF-κB Inflammation/Immunology
    Coronalolic acid, extract from the apical bud of Gardenia sootepenesis Hutch, inhibits TNF-α-induced NF-κB activity and NO production .
    Coronalolic acid
  • HY-122521
    Sootepin D

    		NF-κB Inflammation/Immunology
    Sootepin D (compound 6), a triterpene from the apical bud of Gardenia sootepensis, inhibits TNF-α-induced NF-κB activity with an IC50 of 8.3μM. Sootepin D has anti-inflammatory activity .
    Sootepin D
  • HY-B2098A
    Lucanthone hydrochloride

    		Autophagy Parasite Cancer
    Lucanthone hydrochloride is an endonuclease inhibitor of Apurinic endonuclease-1 (APE-1).
    Lucanthone hydrochloride
  • HY-133795
    Lucanthone N-oxide

    		DNA/RNA Synthesis Others
    Lucanthone N-oxide is the nitrogen oxide of Lucanthone (HY-B2098), an endonuclease inhibitor of Apurinic endonuclease-1 (APE-1) .
    Lucanthone N-oxide
  • HY-B2098R
    Lucanthone (Standard)

    		Autophagy Parasite Reference Standards Cancer
    Lucanthone (Standard) is the analytical standard of Lucanthone. This product is intended for research and analytical applications. Lucanthone is an endonuclease inhibitor of Apurinic endonuclease-1 (APE-1).
    Lucanthone (Standard)
  • HY-P5824
    Anthopleurin-C

    		Sodium Channel Neurological Disease
    Anthopleurin-C (APE 2-1) is a cardiotonic polypeptide that shows a powerful positive inotropic effect .
    Anthopleurin-C
  • HY-100210
    FN-439

    		MMP Inflammation/Immunology Cancer
    FN-439 is a selective collagenase-1 inhibitor. FN-439 inhibits collagenase-1 with an IC50 value of 1 μM. FN-439 can be used for the research of cancer and inflammation .
    FN-439
  • HY-167735
    Salvizol

    Bisdequalinium diacetate

    		 Bacterial Infection
    Salvizol (Bisdequalinium diacetate) is a chemotherapeutic agent with a broad spectrum of bactericidal activity, effective in the apical third of root canals. Salvizol possesses the ability to dissolve organic dentin matrix, facilitating mineralization and tubule exposure. Salvizol maintains a neutral pH, ensuring biological compatibility while exhibiting significant cleansing potency.
    Salvizol
  • HY-109120S
    Odevixibat-d5

    A4250-d5

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-d5
  • HY-109120R
    Odevixibat (Standard)

    A4250 (Standard)

    		 Apical Sodium-Dependent Bile Acid Transporter Reference Standards Metabolic Disease
    Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat (Standard)
  • HY-W338581
    4-tert-Octylphenol monoethoxylate

    		Estrogen Receptor/ERR Others
    4-tert-Octylphenol monoethoxylate is an alkylphenolethoxylate (APE) and a degradation product of non-ionic surfactants (such as 4-tert-octylphenol polyethoxylate). 4-tert-Octylphenol monoethoxylate also possesses non-steroidal estrogenic activity. Additionally, 4-tert-Octylphenol monoethoxylate has been found in wastewater effluent .
    4-tert-Octylphenol monoethoxylate
  • HY-109120S1
    Odevixibat-13C6

    A4250-13C6

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat- 13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-13C6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: